HYBRID EVENT: You can participate in person at Singapore or Virtually from your home or work.

11th Edition of International Conference on
Dental Innovations and Technologies

March 02-04, 2026 | Singapore
Dental 2025

Models to assess microbial dysbiosis and oral microbiome transplantation

Zvi Loewy, Speaker at Dental Conferences
New York Medical College, United States
Title : Models to assess microbial dysbiosis and oral microbiome transplantation

Abstract:

Innovative medical devices have enhanced health care and improved the overall quality of life. Although providing significant medical benefits, there are unfortunately a myriad of diseases that can be attributed to the presence of medical devices. Microbes can colonize on a medical device surface and cause infections, and at times can even lead to malfunction of the device. Microbial species are present either as planktonic cells or incorporated into biofilms. Biofilms evolve from the planktonic state and are characterized as dense micro-communities that grow on inert surfaces and encapsulate themselves with secreted polymers. When organisms form a biofilm, they are able to adapt to environmental change by altering their gene expression patterns. The biofilm structure and corresponding change in gene expression can protect the microbes from disinfectant agents or antibiotics. The resultant biofilm can pose a serious public health issue.

While different types of medical devices harbor biofilms, dental prostheses are some of the most pervasive. The majority of the oral microbes are commensal organisms. Those that are pathogenic microbes can result in oral infections, and at times initiate systemic diseases. The physical nature of biofilms and the survival mechanisms they possess, whether phenotypic adaptability or genetic resistance, leave them impervious to antibiotic treatment. Given the lack of response to traditional antimicrobial therapy, biofilm infections currently pose a great challenge to the world of medicine and odontology.

In this study we focus on (a) the identification and characterization of a novel antimicrobial and (b) establishing a model dental experimental system to evaluate the antimicrobial.

Biography:

Dr. Zvi Loewy is a senior academic leader and an experienced global pharmaceutical – biotechnology executive. He leverages a diversified background in big-pharma senior management, biotech startup creation and academia. Dr. Loewy has served as a board member of the New Jersey Bioscience Center Incubator since 2010. Dr. Loewy’s international experience has included leading international research teams, championing the penetration and commercial launch of healthcare products world-wide, and leading open innovation in the Mid-East. Dr. Loewy received his PhD in Molecular Biology from the Albert Einstein College of Medicine. Dr. Loewy has over 25 issued patients.

Watsapp
a